UNSPSC 51202000: Immunomodulating drugs based on tyrosine Inhibitors and kinase Inhibitors

This classification denotes Immunomodulating drugs made from or based in part on Tyrosine Inhibitors, or Kinase Inhibitors

UNSPSC 51202000 Immunomodulating drugs based on tyrosine inhibitors and kinase inhibitors is a Class code that does not reflect the scope of work actually being solicited under it in recent state and local procurement activity. The sole recent opportunity on record — a July 2026 notice from the Mississippi State Department of Health — concerns Yellow Fever Vaccine procurement, a preventive immunological product unrelated to the tyrosine or kinase inhibitor class of immunomodulating agents the code nominally covers. This mismatch suggests the code sees limited or mislabeled activity in state and local contracting and may not be a reliable indicator of current purchasing patterns in this therapeutic category.

The Mississippi State Department of Health posted a notice of proposed sole source purchase on July 13, 2026, for Yellow Fever Vaccine from Sanofi Pasteur, Inc., with an objection deadline of August 3, 2026. The solicitation is not a competitive RFP, RFQ, IFB, or ITB; it is a sole source designation subject to challenge. The notice does not specify quantity, contract term, estimated value, or pricing. No additional recent state or local opportunities under this code are present in the source material, indicating minimal procurement activity or incorrect code assignment across the state and local market.